Fig. 8
From: Recent advances in pain management based on nanoparticle technologies
a Scheme of study that evaluated the effect of p38 siRNA PLGA nanoparticles on neuropathic pain (reproduced with permission from Ref. [181], Future Medicine 2018). b Schematic of dissolvable MNs mediating local delivery of peptide CGRP antagonist to produce analgesia for the treatment of neuropathic pain (reproduced with permission from Ref. [187], American Chemical Society 2017). siRNA small interfering RNA, PLGA poly(lactic-co-glycolic acid), I.T. injection intrathecal injection, CGRP calcitonin gene-related peptide